Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2013-04-25 Earnings Release
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
THERAVANCE, INC. 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 25, 2013, reporting the financial results for the quarter ended March 31, 2013. It includes a press release as Exhibit 99.1. The text states that the information is being furnished and is not "filed" for purposes of Section 18, indicating it is an earnings release rather than a full quarterly report. The document is short (2737 characters) and primarily announces the earnings results via a press release. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only, not a full interim report. Therefore, the correct classification is ER with high confidence.
2013-04-25 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 25, 2013. It announces that the company's Board of Directors approved plans to separate its businesses into two independent publicly traded companies. It references a conference call and includes a slide presentation (Exhibit 99.1) for the call and a press release (Exhibit 99.2). The content is primarily an announcement of a corporate event and includes a presentation for investors. The presence of a slide presentation for a conference call strongly indicates this is an Investor Presentation. The document length is 4350 characters, which is relatively short but contains substantive information about the business separation and the presentation slides. Therefore, the best classification is Investor Presentation (IP).
2013-04-25 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 17, 2013. It announces a press release regarding the outcome of a meeting of the Pulmonary-Allergy Drugs Advisory Committee to the FDA about a drug under development. The document includes a press release as an exhibit and is signed by the CFO. The content is an announcement of a material event rather than a full financial report or earnings release. The document length is short (3108 characters), and it primarily serves as a regulatory announcement of a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2013-04-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an 'Other Event' related to the FDA posting briefing documents for an advisory committee meeting concerning a drug application. There are no financial statements, earnings data, or detailed management discussion. The document is short (3062 characters) and serves as an announcement of an event rather than a full report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement of a material event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other categories.
2013-04-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2013. It contains a Regulation FD Disclosure about upcoming presentations of clinical study data at a conference. The content is an announcement of information to be presented, not a full financial report or detailed earnings data. The document is relatively short (3499 characters) and does not contain financial statements or detailed analysis. It is primarily a regulatory filing to disclose material information to the market. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2013-03-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an 'Other Event' related to the FDA advisory committee discussing a new drug application involving the company. There are no financial statements, earnings data, or detailed management discussion. The document is short (2791 characters) and serves as a regulatory announcement of an event rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.